President Donald Trump has nominated Heidi Overton, a White House aide, to lead the Food and Drug Administration (FDA), according to a senior administration official. The nomination comes after the departure of former commissioner Marty Makary earlier this year, which has raised concerns about the stability of U.S. drug development. Overton currently serves as the deputy director of the White House Domestic Policy Council and was among several candidates considered for the position. Bloomberg was the first to report her nomination.
Overton recently participated in an executive order signing aimed at revising the childhood vaccine schedule, which includes reducing the number of federally recommended vaccinations and separating the MMR vaccine into three individual shots. During the event, Overton stated, "We do still recommend the measles vaccine for all children, but we want parents to be informed about the timing and to have the option to separate them out."
Some analysts have expressed concerns regarding Overton's lack of experience in leadership roles, with Chris Meekins, a Raymond James analyst and former Trump health official, suggesting that her confirmation could lead to further instability within the FDA. Conversely, Brian Blase, president of the Paragon Health Institute, praised Overton as a "great choice," highlighting her character and commitment to improving healthcare.
The nomination will require approval from the Senate, and it remains to be seen if Overton will face opposition from lawmakers, particularly due to her recent involvement in vaccine-related discussions.